Oceania

Genetic disease research imitating function and architecture of organs

Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.

Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.

At the frontier of human cellular neuroscience research

Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.

His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).


His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.

Junior Fellowship to develop vaccine for bacteria that cause ear infections

Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.

The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.

Investigating the benefits of donor human milk for preterm infants

Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.

Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.

The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.

Superslayer taking on antibiotic-resistant bacteria

Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.

Touched by bowel cancer and chasing science outcomes

Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.

Seeking discoveries in earlier bowel cancer detection

Associate Professor Susan Woods is a cancer research focused on eradicating bowel cancer through earlier detection and investigating the DNA related from colorectal cancer cells. She leads the Gut Cancer Research Group at the University of Adelaide and SAHMRI and with her team is researching new treatments for advanced disease.

World-first clinical trial improves patient outcomes for kidney transplants (2023)

A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.

Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.

The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.

RESEARCH IMPACT SAHMRI, SOUTH AUSTRALIA (2023)

South Australian Health and Medical Research Institute, also known as SAHMRI has had significant impacts in various areas over the past ten years, and this year is celebrating its 10 year anniversary with a week of events.

Ahead of the anniversary, Executive Director, Professor Maria Makrides spoke to Bench Side Story about 3 achievements in the past 10 years that have had significant impact

In his father’s footsteps as a kidney transplant specialist

Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.

Scroll to top